A practical guide about biosimilar data for health care providers treating inflammatory diseases
Joseph Markenson,1,2 Daniel F Alvarez,3 Ira Jacobs,4 Carol Kirchhoff5 1Department of Rheumatology, 2Department of Medicine, Hospital for Special Surgery, New York, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Chesterfield, MO, USA Abstract: To make informed dec...
Saved in:
Main Authors: | Markenson J, Alvarez DF, Jacobs I, Kirchhoff C |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/f9f26565da4f46dba6052ea2c7079196 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biosimilars and the extrapolation of indications for inflammatory conditions
by: Tesser JRP, et al.
Published: (2017) -
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
by: Yazici Y, et al.
Published: (2018) -
Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
by: Al Sulais E, et al.
Published: (2020) -
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021) -
A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population
by: Yazici Y, et al.
Published: (2018)